Generer rapport
Orifarm Generics Holding A/S
Energivej 15, Lindved, 5260 Odense S, CVR 27347223
Branche: Ikke-finansielle holdingselskaber
Virksomhedsform
Aktieselskab
Etableret
2003
Størrelse
Mikro
Ansatte
3
Omsætning
-
DKK
Bruttofortj.
309
MDKK
Primært resultat (EBIT)
206
MDKK
Årets resultat
130
MDKK
Egenkapital
2.108
MDKK
Reklamebeskyttet virksomhed
Denne virksomhed er reklamebeskyttet. Det betyder bl.a. at oplysningerne ikke må bruges til reklamehenvendelser. annonce
Flere nøgletal og analyser?
Med en Bisbase Premium konto får du flere nøgletal for både virksomheder, koncerner og brancher samt adgang til eksklusive brancher indeholdende virksomheder nøje sammensat af eksperter. Og vil du lave dine egne analyser kan du også det! Det tager få minutter at få adgang - og det behøver ikke at koste dig noget!
Rang Årets resultat
Rang i branche
255/95.264
"Top 10%"
Rang i Danmark
1.231/343.300
"Top 10%"
Direktion top 3
Bestyrelse top 3
| Hans Carl Bøgh-Sørensen 22 | Bestyrelsesformand |
| Erik Sandberg 17 | Bestyrelsesmedlem |
| Birgitte Bøgh-Sørensen 11 | Bestyrelsesmedlem |
Legale ejere top 3
| 100% | Orifarm Group A/S | DK |
Tegningsregler
Selskabet tegnes af den administrerende direktør og ét bestyrelsesmedlem i forening, af bestyrelsesformanden alene eller af to bestyrelsesmedlemmer i forening.
Stamoplysninger baseret på CVR
| Navn | Orifarm Generics Holding A/S |
| Binavne | Orifarm Healthcare Holding A/S Vis mere |
| CVR | 27347223 |
| Adresse | Energivej 15, Lindved, 5260 Odense S |
| Branche | Ikke-finansielle holdingselskaber [642020] |
| Etableret | 12-09-2003 (20 år) |
| Første regnskabsperiode | 01-01-2003 til 31-12-2003 |
| Virksomhedsform | Aktieselskab |
| Antal ansatte | 3 (årsværk:2) |
| Reklamebeskyttelse | Ja |
| Revisor | Deloitte Statsautoriseret Revisionspartnerselskab siden 13-10-2011 |
| Regnskabsperiode | 01-01 til 31-12 |
| Selskabskapital | 1.300.000 DKK 1.200.000 DKK (10-09-2004 - 06-07-2015) 1.100.000 DKK (09-12-2003 - 09-09-2004) 1.000.000 DKK (12-09-2003 - 08-12-2003) |
| Vedtægter seneste | 15-02-2024 |
Medlem af brancherne
- Ikke-finansielle holdingselskaberNACE6 indeholdende 109.509 virk.
- Holdingselskabers virksomhedNACE3 indeholdende 116.007 virk.
- Pengeinstitut- og finansieringsvirksomhed undtagen forsikring og NACE2 indeholdende 148.981 virk.
- Pengeinstitut- og finansvirksomhed, forsikringNACE1 indeholdende 151.955 virk.
Formål
Selskabets formål er at besidde kapitalandele i datterselskaberne og at erhverve og besidde immaterielle og materielle aktiver, som knytter sig til disse. Endvidere er selskabets formål at forestå forretningsudvikling og ledelsesmæssige opgaver for datterselskaber samt dertil beslægtede opgaver, der måtte forekomme i koncernen.
Regnskab
| 2022 | 2021 | 2020 | |
|---|---|---|---|
| Valuta/enhed | 000' DKK | 000' DKK | 000' DKK |
| Omsætning | - - | - - | - - |
| Bruttofortjeneste | 309.186 +62% | 190.643 +1.382% | 12.868 +2% |
| Årets resultat | 130.350 -39% | 213.053 +87% | 114.171 +58% |
| Egenkapital | 2.108.078 -15% | 2.479.781 +494% | 417.490 +38% |
| Balance | 3.718.630 +16% | 3.214.708 +412% | 627.598 +22% |
Ledelsesberetning
Development in activities and financesThe result for 2022 shows a profit of kDKK 130,350 compared to a profit of kDKK 213,053 in 2021.
In 2022, Orifarm Generics Holding A/S has acquired intangible rights from a sister company within the Orifarm Group.
Particular risks
Operating conditions
For the business area Orifarm Healthcare, Orifarm Group’s policy states that infringing patent rights should be avoided. However, patent holders have a commercial interest in defending market monopolies and manufactures of generic products have an interest in challenging the market at patent expiry. This makes disputes and litigation difficult to avoid. Orifarm Group is from time to time involved in pending legal proceedings. The outcome of these may affect Orifarm Group's earnings. Following the acquisition of a range of pharmaceuticals from Takeda, including a portfolio of patents and trademarks, Orifarm shall take the necessary measures to protect these from 3rd party infringements.
The Company is not currently involved in any major pending litigation of this kind.
Financial matters
The Company exposed to fluctuations in foreign exchange rates and interest rate levels. These risks are mitigated in accordance with the Group’s policy. Exchange rate risks are primarily related to the currencies SEK, NOK and PLN.
The Company’s financial risks, including its cash management and management of credits, are managed at a corporate level to ensure a balanced risk profile.
In 2022, Orifarm Generics Holding A/S has acquired intangible rights from a sister company within the Orifarm Group.
Particular risks
Operating conditions
For the business area Orifarm Healthcare, Orifarm Group’s policy states that infringing patent rights should be avoided. However, patent holders have a commercial interest in defending market monopolies and manufactures of generic products have an interest in challenging the market at patent expiry. This makes disputes and litigation difficult to avoid. Orifarm Group is from time to time involved in pending legal proceedings. The outcome of these may affect Orifarm Group's earnings. Following the acquisition of a range of pharmaceuticals from Takeda, including a portfolio of patents and trademarks, Orifarm shall take the necessary measures to protect these from 3rd party infringements.
The Company is not currently involved in any major pending litigation of this kind.
Financial matters
The Company exposed to fluctuations in foreign exchange rates and interest rate levels. These risks are mitigated in accordance with the Group’s policy. Exchange rate risks are primarily related to the currencies SEK, NOK and PLN.
The Company’s financial risks, including its cash management and management of credits, are managed at a corporate level to ensure a balanced risk profile.
05-06-2023